Friday, Aug 07, 2020 | Last Update : 04:06 PM IST

136th Day Of Lockdown

Maharashtra47977931637516792 Tamil Nadu2791442210874571 Andhra Pradesh1967891128701753 Karnataka158254802812897 Delhi1415311271244059 Uttar Pradesh108974634021918 West Bengal86754610231902 Telangana7525753239601 Gujarat65704485612529 Bihar6203140760349 Assam4816233429115 Rajasthan4667932832732 Haryana3779631226448 Odisha3768124483258 Madhya Pradesh3508225414912 Kerala279561629988 Jammu and Kashmir2239614856417 Punjab1901512491462 Jharkhand140705199129 Chhatisgarh10109761369 Uttarakhand8008484795 Goa7075511460 Tripura5520367528 Puducherry4147253758 Manipur301818147 Himachal Pradesh2879171013 Nagaland24056594 Arunachal Pradesh179011053 Chandigarh120671520 Meghalaya9173305 Sikkim7832971 Mizoram5022820
  Science   05 Jul 2020  Remdesivir gets conditional EU clearance to be used in severe COVID-19 patients

Remdesivir gets conditional EU clearance to be used in severe COVID-19 patients

REUTERS
Published : Jul 5, 2020, 1:54 pm IST
Updated : Jul 5, 2020, 1:54 pm IST

The move comes just days after Gilead allocated nearly all of its supply of remdesivir for the next three months to the US

Vials of the drug 'remdesivir' during a press conference concerning the start of a study with the Ebola drug to treat severely ill patients afflicted with coronavirus COVID-19, at The University Hospital Eppendorf (UKE) in Hamburg, northern Germany, amidst the global pandemic. (AFP)
 Vials of the drug 'remdesivir' during a press conference concerning the start of a study with the Ebola drug to treat severely ill patients afflicted with coronavirus COVID-19, at The University Hospital Eppendorf (UKE) in Hamburg, northern Germany, amidst the global pandemic. (AFP)

Brussels: The European Commission said on Friday it had given conditional approval for the use of antiviral remdesivir in severe COVID-19 patients following an accelerated review process, making it the region’s first authorised therapy to treat the virus.

The move comes just a week after the European Medicines Agency (EMA) gave its go-ahead for the drug, produced by Gilead Sciences, to be used in adults and adolescents from 12 years of age who are also suffering from pneumonia and require oxygen support.

 

It also comes just days after the company allocated nearly all of its supply of remdesivir to the United States over the next three months, stirring concerns about availability elsewhere.

“We will leave no stone unturned in our efforts to secure efficient treatments or vaccine against the coronavirus,” said Stella Kyriakides, EU Commissioner for Health and Food Safety, in a statement.

The Commission said on Wednesday it was in negotiations with Gilead to obtain doses of remdesivir for the 27 European Union countries.

Remdesivir is in high demand after the intravenously-administered medicine helped to shorten hospital recovery times in a clinical trial.

 

It is believed to be most effective in treating COVID-19 patients earlier in the course of disease than other therapies like the steroid dexamethasone.

Still, because remdesivir is given intravenously over at least a five-day period it is generally being used on patients sick enough to require hospitalisation.

The EU’s green light broadens the use of remdesivir around the world - the United States has cleared it for emergency use and it is also approved as a COVID-19 therapy in Japan, Taiwan, India, Singapore and the United Arab Emirates, Gilead said on Friday.

A conditional marketing authorisation is one of the EU regulatory mechanisms created to facilitate early access to medicines that fulfil an unmet medical need, including those for emergency situations in response to public health threats such as the current pandemic, the Commission said.

 

The approval is valid for one year in the bloc and can be extended or converted into an unconditional marketing authorisation if all necessary data are available on its efficacy and side effects.

The agency reviews data as they become available on a rolling basis, while development is still ongoing. The EMA’s rolling review began at the end of April.

Tags: remdesivir, gilead sciences, us, three months supply, european commission approval, coronavirus, covid-19